Drugs /

vmd-928

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable, selective inhibitor of tropomyosin receptor kinase A (TrkA; neurotrophic tyrosine receptor kinase (NTRK) type 1; NTRK1; TRK1-transforming tyrosine kinase protein), with potential antineoplastic activity. Upon oral administration, VMD-928 specifically targets and binds to TrkA, inhibits neurotrophin-TrkA interaction and prevents TrkA activation. This prevents the activation of downstream signaling pathways and inhibits cell growth in tumors that overexpress TrkA. Uncontrolled TrkA signaling plays an important role in tumor cell growth, survival, invasion and treatment resistance.

Clinical Trials

View Clinical Trials for vmd-928

Vmd-928 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating vmd-928, 1 is phase 1 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for vmd-928 clinical trials.

Acute myeloid leukemia, adenoid cystic carcinoma, and breast carcinoma are the most common diseases being investigated in vmd-928 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Vmd-928
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vmd-928 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
vmd 928, vmd928, ntrk1 inhibitor vmd-928, trka inhibitor vmd-928
Drug Target(s) [2]:
NTRK1
NCIT ID [1]:
C153116

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.